Cargando…

New Onset and Exacerbation of Psoriasis Following COVID-19 Vaccination: A Review of the Current Knowledge

COVID-19 vaccination was the main measure to overcome the pandemic. As with other drugs and vaccines, mild to moderate adverse events have been reported following vaccination. In addition, several cutaneous reactions have been described. In particular, there are several reports investigating de novo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Potestio, Luca, Battista, Teresa, Cacciapuoti, Sara, Ruggiero, Angelo, Martora, Fabrizio, Fornaro, Luigi, Camela, Elisa, Megna, Matteo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452075/ https://www.ncbi.nlm.nih.gov/pubmed/37626687 http://dx.doi.org/10.3390/biomedicines11082191

Ejemplares similares

Biologics for the Management of Erythrodermic Psoriasis: An Updated Review
por: Potestio, Luca, et al.
Publicado: (2023)

Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era?
por: Megna, Matteo, et al.
Publicado: (2023)

Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge
por: Ruggiero, Angelo, et al.
Publicado: (2022)

Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature
por: Potestio, Luca, et al.
Publicado: (2023)

Nail Psoriasis: An Updated Review of Currently Available Systemic Treatments
por: Battista, Teresa, et al.
Publicado: (2023)

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data
por: Martora, Fabrizio, et al.
Publicado: (2023)

Towards Personalized Medicine in Psoriasis: Current Progress
por: Camela, Elisa, et al.
Publicado: (2022)

Long-Term Efficacy and Safety of Risankizumab for Moderate to Severe Psoriasis: A 2-Year Real-Life Retrospective Study
por: Megna, Matteo, et al.
Publicado: (2023)

Safety and Efficacy of Covid-19 Vaccination in Patients Undergoing Biological Treatments for Psoriasis
por: Potestio, Luca, et al.
Publicado: (2023)

Risankizumab treatment in psoriasis patients who failed anti‐IL17: A 52‐week real‐life study
por: Megna, Matteo, et al.
Publicado: (2022)

Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: Results from an Italian single‐center retrospective study in a real‐life setting
por: Megna, Matteo, et al.
Publicado: (2022)

Onset of vitiligo in a psoriasis patient on ixekizumab
por: Marasca, Claudio, et al.
Publicado: (2021)

Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature
por: Martora, Fabrizio, et al.
Publicado: (2023)

The Impact of COVID-19 Vaccination on Inflammatory Skin Disorders and Other Cutaneous Diseases: A Review of the Published Literature
por: Martora, Fabrizio, et al.
Publicado: (2023)

New-Onset Psoriatic Arthritis under Biologics in Psoriasis Patients: An Increasing Challenge?
por: Megna, Matteo, et al.
Publicado: (2021)

Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study
por: Ruggiero, Angelo, et al.
Publicado: (2023)

A case of scalp psoriasis resistant to ixekizumab treated with bimekizumab
por: Megna, Matteo, et al.
Publicado: (2023)

The Role of Teledermatology During the COVID-19 Pandemic: A Narrative Review
por: Ruggiero, Angelo, et al.
Publicado: (2022)

Efficacy and Safety of Anti-TNF Biosimilars for Psoriasis in Pediatric and Geriatric Populations: A 72-Week Real-Life Study
por: Megna, Matteo, et al.
Publicado: (2022)

Herpes Zoster and COVID-19 Vaccination: A Narrative Review
por: Potestio, Luca, et al.
Publicado: (2023)

Concomitant Severe Psoriasis and Bullous Pemphigoid Induced by COVID-19
por: Martora, Fabrizio, et al.
Publicado: (2023)

Guselkumab-induced vitiligo in a patient with psoriatic arthritis
por: Martora, Fabrizio, et al.
Publicado: (2023)

Letter to the editor regarding article “Yalici‐Armagan B, Tabak GH, Dogan‐Gunaydin S, Gulseren D, Akdogan N, Atakan N. Treatment of psoriasis with biologics in the early COVID‐19 pandemic: A study examining patient attitudes toward the treatment and disease course. J Cosmet Dermatol. 2021;00:1–5”
por: Potestio, Luca, et al.
Publicado: (2021)

Effectiveness of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis Located in Difficult-to-Treat Areas
por: Cacciapuoti, Sara, et al.
Publicado: (2023)

Efficacy and Safety of Tildrakizumab in a Patient with Chronic HBV Infection
por: Potestio, Luca, et al.
Publicado: (2023)

A case of pediatric psoriasis successfully and rapidly treated with ixekizumab
por: Megna, Matteo, et al.
Publicado: (2021)

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence
por: Ruggiero, Angelo, et al.
Publicado: (2022)

Letter to the editor regarding the article “Oguz Topal I, Kara Polat A, Zindancı İ, et al. Adherence to systemic therapy in patients with psoriasis during the COVID‐19 pandemic: A multicenter study. J Cosmet Dermatol. 2021;10.1111/jocd.14610.”
por: Potestio, Luca, et al.
Publicado: (2022)

A case of severe psoriatic arthritis with hands flexion contracture and palmar psoriasis successfully treated with guselkumab
por: Megna, Matteo, et al.
Publicado: (2022)

Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study
por: Megna, Matteo, et al.
Publicado: (2022)

Teledermatology for Common Inflammatory Skin Conditions: The Medicine of the Future?
por: Martora, Fabrizio, et al.
Publicado: (2023)

A case of erythrodermic psoriasis successfully treated with apremilast
por: Megna, Matteo, et al.
Publicado: (2021)

A case of linear psoriasis in a young patient with Down syndrome and review of the literature
por: Martora, Fabrizio, et al.
Publicado: (2022)

Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience
por: Martora, Fabrizio, et al.
Publicado: (2023)

Ocular Manifestations in Psoriasis Screening (OcMaPS) Questionnaire: A Useful Tool to Reveal Misdiagnosed Ocular Involvement in Psoriasis
por: Ruggiero, Angelo, et al.
Publicado: (2021)

Treatment of pediatric psoriasis with TNF-antagonists: a real-life single-center case series()
por: Megna, Matteo, et al.
Publicado: (2022)

Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature
por: Martora, Fabrizio, et al.
Publicado: (2022)

Teledermatology and Inflammatory Skin Conditions during COVID-19 Era: New Perspectives and Applications
por: Marasca, Claudio, et al.
Publicado: (2022)

Development of a Patient-Reported Outcome Measure (PROM) for Dysgeusia During Treatment With Smoothened (SMO) Inhibitors for Basal Cell Carcinomas: The SMO-iD Questionnaire
por: Camela, Elisa, et al.
Publicado: (2023)

Teledermatology: A useful tool also after COVID‐19 era?
por: Megna, Matteo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6p7kdluo1nmas6rdih1fgjohno